Back to top
more

Omeros (OMER)

(Delayed Data from NSDQ)

$3.15 USD

3.15
172,888

+0.09 (2.94%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.14 -0.01 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for OMER

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Omeros Corporation [OMER]

Reports for Purchase

Showing records 161 - 180 ( 423 total )

Company: Omeros Corporation

Industry: Medical - Products

Record: 161

10/17/2016

Daily Note

Pages: 6

Initial Results for OMS721 Treatment of Complement Related Kidney Diseases Look Promising, in Our View; Reiterate OUTPERFORM and $56 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 162

10/04/2016

Daily Note

Pages: 45

October and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 163

09/01/2016

Daily Note

Pages: 44

September and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 164

08/18/2016

Industry Report

Pages: 18

HEALTHCARE - 2016 PacGrow Healthcare Conference Day 2

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 165

08/11/2016

Company Report

Pages: 7

Financing Covers the Development of OMS721 and Pipeline; Reiterate OUTPERFORM but Reducing Price Target to $56 due to Share Count Increase

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 166

08/09/2016

Company Report

Pages: 8

Q2 Financials: Beat and Beat--More OMS721 Phase 2 Results - Start of Phase 3 in H2; Reiterate OUTPERFORM and $62 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 167

08/01/2016

Daily Note

Pages: 46

August and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 168

07/15/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 169

07/01/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 4

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 170

07/01/2016

Industry Report

Pages: 46

July and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 171

06/24/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of June 27

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 172

06/03/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of June 6

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 173

05/31/2016

Daily Note

Pages: 43

June and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 174

05/10/2016

Company Report

Pages: 8

Q1 Update: OMIDRIA Sales Accelerating into Q2 and 2016 Catalysts Suggest Buying on Weakness to Us; Reiterate OUTPERFORM and $62 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 175

05/09/2016

Daily Note

Pages: 43

May and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 176

04/11/2016

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 177

04/01/2016

Daily Note

Pages: 42

April and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 178

03/09/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 179

03/08/2016

Company Report

Pages: 6

Growing >70% Again

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 180

03/08/2016

Company Report

Pages: 9

Q4/FY:15 Update; Omidria Sales Beat Consensus; Phase 3 Trial for OMS721 Set to Begin Later this Year; Reiterate OUTPERFORM and $62 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party